Bausch + Lomb Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Brent Saunders

Chief executive officer

US$45.3m

Total compensation

CEO salary percentage	3.1%
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	1.2yrs
Board average tenure	2.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brent Saunders's remuneration changed compared to Bausch + Lomb's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$337m
Dec 31 2023	US$45m	US$1m	-US$260m

Compensation vs Market: Brent's total compensation ($USD45.31M) is above average for companies of similar size in the German market ($USD3.27M).

Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.

CEO

Brent Saunders (54 yo)

1.3yrs

Tenure

US$45,309,051

Compensation

Mr. Brenton L. Saunders, J. D., also known as Brent, is CEO & Chairman of the Board at Bausch & Lomb Incorporated since 2023. He is CEO & Chairman of the Board at Bausch + Lomb Corporation since March 06,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Brenton L. Saunders	CEO & Chairman	1.3yrs	US$45.31m	no data
Osama Eldessouky	Executive VP & CFO	2.4yrs	US$4.76m	0.0048% $ 236.6k
A. Robert Bailey	Executive VP & Chief Legal Officer	1.2yrs	US$5.21m	0.0086% $ 427.6k
Yehia Hashad	Executive VP of Research & Development and Chief Medical officer	2.4yrs	US$2.66m	0.0032% $ 161.2k
Andrew Stewart	President of Global Pharmaceuticals & International Consumer	1.4yrs	US$1.93m	0.0020% $ 100.2k
Alan Waterhouse	Executive VP and Chief Supply Chain & Operations Officer	1.4yrs	no data	no data
Frederick Munsch	Senior VP	no data	no data	0.0011% $ 57.0k
Jonathon Kellerman	Chief Compliance Officer	less than a year	no data	no data
T.J. Crawford	Chief Communications Officer	less than a year	no data	no data
Manisha Narasimhan	Chief Corporate Development & Digital Officer	less than a year	no data	no data
Asli Gevgilili	Executive VP & Chief Human Resources Officer	less than a year	no data	no data
Luc Bonnefoy	President of Surgical	no data	no data	0.00077% $ 38.2k

1.2yrs

Average Tenure

54yo

Average Age

Experienced Management: S2L's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Brenton L. Saunders	CEO & Chairman	1.3yrs	US$45.31m	no data
Thomas Ross	Lead Independent Director	1.3yrs	US$396.30k	0.0036% $ 176.1k
John Paulson	Independent Director	2.2yrs	US$312.46k	0.0072% $ 357.6k
Sarah Kavanagh	Independent Director	2.2yrs	US$337.50k	0.0016% $ 81.8k
Brett Icahn	Independent Director	2yrs	US$312.50k	0.0074% $ 368.1k
Russel Robertson	Independent Director	2.2yrs	US$327.45k	0.0037% $ 184.0k
Andrew von Eschenbach	Independent Director	2.2yrs	US$327.50k	0.0036% $ 176.1k
Karen Ling	Independent Director	less than a year	no data	0.00075% $ 37.2k
Nathalie Bernier	Independent Director	2.2yrs	US$324.95k	0.000060% $ 3.0k
Gaoxiang Hu	Independent Director	2yrs	US$335.00k	0.0074% $ 368.1k

2.1yrs

Average Tenure

64yo

Average Age

Experienced Board: S2L's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Bausch + Lomb Management

Management criteria checks 0/4

Key information

Recent management updates

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Recent updates

Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses

Bausch + Lomb Corporation Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States

Bausch + Lomb Corporation Receives Health Canada Approval for Envista Envy™? Full Visual Range Intraocular Lens

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.26 loss in 1Q 2023)

Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Bausch + Lomb Corporation to Report Q1, 2024 Results on May 01, 2024

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Full year 2023 earnings released: US$0.74 loss per share (vs US$0.017 profit in FY 2022)

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2024

Bausch + Lomb Corporation to Report Q4, 2023 Results on Feb 21, 2024

Bausch + Lomb Corporation Receives FDA Approval for TENEO Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

New major risk - Financial position

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.051 loss in 3Q 2022)

Bausch + Lomb Corporation Raises Revenue Guidance for the Full Year of 2023

Bausch + Lomb Will Present New Scientific Data and Analyses At American Academy of Ophthalmology Annual Meeting

Bausch + Lomb Corporation to Report Q3, 2023 Results on Nov 01, 2023

Bausch + Lomb Corporation Launches LUMIFY EYE ILLUMINATIONS in the United States

Bausch + Lomb Corporation Launches MIEBO (Perfluorohexyloctane Ophthalmic Solution) in the United States

Second quarter 2023 earnings released: US$0.091 loss per share (vs US$0.014 profit in 2Q 2022)

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation to Report Q2, 2023 Results on Aug 02, 2023

Bausch + Lomb Corporation (NYSE:BLCO) agreed to acquire Blink® product line of eye and contact lens drops of Johnson & Johnson Vision for approximately $110 million.

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

Bausch + Lomb Corporation to Present the Results of 11 Scientific Poster Presentations Inviding the Company's Consumer, Vision Care and Pharmaceutical Products

Now 20% undervalued

Bausch + Lomb Corporation Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United States

Bausch + Lomb Corporation Launches Bausch + Lomb Infuse®? Multifocal Silicone Hydrogel Contact Lenses in the United States

Bausch + Lomb Corporation Announces Executive Changes

Now 21% undervalued

Bausch + Lomb Corporation and Novaliq Announce Fda Approval of Miebo™? (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Bausch + Lomb and Modulight Announces FDA Approval of ML6710i Photodynamic Laser

Bausch + Lomb Corporation, Annual General Meeting, Apr 24, 2023

Bausch + Lomb Corporation to Report Q4, 2022 Results on Feb 22, 2023

Bausch + Lomb Corporation (NYSE:BLCO) acquired AcuFocus, Inc.

Bausch + Lomb Corporation Announces the U.S. Introduction of Preservision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb Corporation Enters into CEO Separation Agreement with Joseph C. Papa

Bausch + Lomb Corporation Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

Third quarter 2022 earnings released

Bausch + Lomb Corporation Revises Revenue Guidance for the Year 2022

Bausch + Lomb Corporation Announces Introduction of Project Watson Health Care Products for Dogs in the United States

Bausch + Lomb Corporation to Report Q3, 2022 Results on Nov 02, 2022

Bausch + Lomb Corporation Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation with Vitamin D

Bausch + Lomb and Novaliq GmbH Announces U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)

Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.13 in 2Q 2021)

Bausch + Lomb Corporation Reaffirms Earnings Guidance for the Full Year 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age